Medivation Takes Hard Line Against Sanofi’s ‘Opportunistic’ Offer
CEO David Hung and and Chief Operating Officer Marion McCourt updated employees following a first-quarter financials conference call last week.
The San Francisco Business Times:
Medivation Appeals To Its 'Great Teams' Of Employees In Sanofi Saga. But How Long Can It Repel Buyer?
Takeover target Medivation Inc. ratcheted up its war of words with suitor Sanofi SA, saying in a letter to employees Thursday that the French drug maker's $9.3 billion "lowball proposal" is "unsolicited" and "opportunistic." (Leuty, 5/8)
In other pharmaceutical news —
The San Francisco Business Times:
East Bay Site Plays Key Role As Diabetes Drug Developer Aims At FDA Approval
Intarcia Therapeutics Inc.'s big push toward a diabetes treatment approval will mean more work for the company's Hayward manufacturing site. (Seiffert, 5/8)